RSV in Paediatrics - Patient Pathway at Alere

RSV in Paediatrics - Patient Pathway

If you were the patient, what would you want?

At the 2011 Biomedical Science Congress Alere conducted market research and analysed the views of over 700 laboratory based scientists.

We asked delegates could the implementation of Pathway B bring benefits to your hospital? Find the results below.

Of the 672 people that anwswered the question 95% said that Pathway B using BinaxNOW RSV could bring benefits to their hospital.

Also 103 of those asked for a link to the publications relating to that pathway.

To view a copy of the evidence relating to this pathway click on the download tab below

Pathway B in Practice

The Royal Hospital for Sick Children, Edinburgh, reported that the number of cubicle-days saved by having POCT results available at point of care compared with being available at 24hrs from the laboratory (i.e. direct cohort admission) was 183; equivalent to 11.4 cubicle-days/week. BinaxNOW® RSV.

In conclusion, the study shows that the use of RSV POCT in a paediatric emergency department allows the implementation of a safe, accurate and efficient cohorting system. We believe the strategy to be cost-effective, and it avoids a substantial and unnecessary use of cubicle time, allowing cubicles to be used by other patients.

Kate Templeton,
Microbiology Department

Rapid testing for respiratory syncytial virus in a paediatric emergency department: benefits for infection control & bed management’
J.M Mills, J. Harper, D. Broomfield, K.E.Templeton

Connecting withEmergency Medicine

Product Areas